Scientists make critical insights into T-cell development

August 11, 2017
Scientists make critical insights into T-cell development
Credit: Monash University

Mutations in the gene encoding the enzyme protein tyrosine phosphatase N2 (PTPN2) have been associated with the development of autoimmune disease including Type 1 diabetes, Crohn's Disease and rheumatoid arthritis.

In important fundamental research, Monash University researchers have identified a crucial part of the enzyme's role in early T-cell , and have shown that decreased levels of this enzyme can lead to the type of T-cells that can contribute to the development of autoimmune disease.

Autoimmune diseases represent a broad spectrum of diseases, which arise when immune responses are directed against, and damage, the body's own tissues. Collectively their incidence exceeds that of cancer and and they are a leading cause of death and disability, in particular in the Western world.

The Monash Biomedicine Discovery Institute researchers had already shown in studies over the years that decreased levels of PTPN2 result in T-cells attacking the body's own cells and tissues.

In a paper published in the Journal of Experimental Medicine, they drilled deeper, exploring roles for the enzyme in early T-cell development and the development of particular T-cell subsets (αβ and γδ) implicated in the development of different autoimmune and inflammatory diseases.

By removing the gene coding for PTPN2 in laboratory trials, the scientists found that the developmental process for T-cells was skewed towards the generation of γδ T cells with pro-inflammatory properties that are known to contribute to the development of different diseases including Irritable Bowel Disease, Crohn's Disease and rheumatoid arthritis.

"This is an important advance in our understanding of critical checkpoints in T-cell development," lead researcher Professor Tony Tiganis said.

"It helps decide whether the progenitors go on to become T-cells or something else; if they become one type of T-cell or another type," he said.

As part of the study, the researchers looked at the pathways that PTPN2 regulates.

"There are drugs that target some of these pathways – potentially we might be able to use existing drugs to target these pathways in the context of autoimmune and to help a subset of patients with a deficiency in this gene, although that is a long way off," Professor Tiganis said.

First author Dr Florian Wiede said, "Understanding the mechanisms that govern early T-cell development and how these are altered in human disease may ultimately afford opportunities for novel treatments. This is very exciting."

Explore further: New gene mutations found in white blood cells in patients with rheumatoid arthritis

More information: Florian Wiede et al. PTPN2 regulates T cell lineage commitment and αβ versus γδ specification, The Journal of Experimental Medicine (2017). DOI: 10.1084/jem.20161903

Related Stories

New gene mutations found in white blood cells in patients with rheumatoid arthritis

June 21, 2017
Gene mutations accumulating in cells are typical of the development of cancer. Finnish researchers have found that a similar accumulation of mutations occurs also in some patients with rheumatoid arthritis.

Tpl2 enzyme may be target for treating autoimmune diseases

May 22, 2015
New research at the University of Georgia has found that the presence of Tpl2—an enzyme that regulates inflammation—controls the activation of T cells during colitis, an autoimmune disease that occurs when the inner lining ...

Immune cell death safeguards against autoimmune disease

September 6, 2012
Researchers at the Walter and Eliza Hall Institute have discovered that a pair of molecules work together to kill so-called 'self-reactive' immune cells that are programmed to attack the body's own organs. The finding is ...

Preventing too much immunity

December 27, 2016
Scientists at the Immunology Frontier Research Center (IFReC), Osaka University, Japan, report a new molecular mechanism that could explain the cause of some autoimmune diseases.

Trigger for autoimmune disease identified

May 11, 2017
Researchers at National Jewish Health have identified a trigger for autoimmune diseases such as lupus, Crohn's disease and multiple sclerosis. The findings, published in the April 2017 issue of Journal of Clinical Investigation, ...

Battle of the bulge occurs in the liver

June 20, 2014
(Medical Xpress)—An international team of scientists led by Monash University researchers has shown how free radicals contribute to type 2 diabetes, obesity and fatty liver disease.

Recommended for you

Exposure to larger air particles linked to increased risk of asthma in children

December 15, 2017
Researchers at The Johns Hopkins University report statistical evidence that children exposed to airborne coarse particulate matter—a mix of dust, sand and non-exhaust tailpipe emissions, such as tire rubber—are more ...

Bioengineers imagine the future of vaccines and immunotherapy

December 14, 2017
In the not-too-distant future, nanoparticles delivered to a cancer patient's immune cells might teach the cells to destroy tumors. A flu vaccine might look and feel like applying a small, round Band-Aid to your skin.

Immune cells turn back time to achieve memory

December 13, 2017
Memory T cells earn their name by embodying the memory of the immune system - they help the body remember what infections or vaccines someone has been exposed to. But to become memory T cells, the cells go backwards in time, ...

Steroid study sheds light on long term side effects of medicines

December 13, 2017
Fresh insights into key hormones found in commonly prescribed medicines have been discovered, providing further understanding of the medicines' side effects.

The immune cells that help tumors instead of destroying them

December 12, 2017
Lung cancer is the leading cause of cancer-associated deaths. One of the most promising ways to treat it is by immunotherapy, a strategy that turns the patient's immune system against the tumor. In the past twenty years, ...

Cancer gene plays key role in cystic fibrosis lung infections

December 12, 2017
PTEN is best known as a tumor suppressor, a type of protein that protects cells from growing uncontrollably and becoming cancerous. But according to a new study from Columbia University Medical Center (CUMC), PTEN has a second, ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.